For the quarter ending 2025-09-30, DMAC made $483K in revenue. -$8,556K in net income. Net profit margin of -1771.43%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 6,437 | 5,822 | ||
| General and administrative | 2,596 | 2,185 | ||
| Operating loss | -9,033 | -8,007 | ||
| Other income, net | 419 | 314 | ||
| Loss before income tax expense | -8,614 | -7,693 | ||
| Income tax expense | 6 | 6 | ||
| Net loss | -8,620 | -7,699 | ||
| Unrealized gain on marketable securities | 64 | -19 | ||
| Net loss and comprehensive loss | -8,556 | -7,718 | ||
| Basic and diluted net loss per share (in dollars per share) | -0.17 | -0.18 | ||
| Weighted average shares outstandingbasic and diluted (in shares) | 49,630,119 | 42,957,619 | ||
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)